- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alvotech SA DRC (ALVOsdb)
Alvotech SA DRC stock price live, this page displays ST ALVOsdb stock exchange data. View the ALVOsdb premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alvotech SA DRC real time stock price chart below.
What Is the Alvotech SA DRC Stock Price Today?
The Alvotech SA DRC stock price today is 36.65.
What Is the Stock Symbol for Alvotech SA DRC?
The stock symbol for Alvotech SA DRC is "ALVOsdb."
What Stock Exchange Does Alvotech SA DRC Trade On?
Alvotech SA DRC is listed and trades on the Stockholm stock exchange.
Is Alvotech SA DRC a Good Stock to Buy?
Determining whether Alvotech SA DRC, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALVOsdb quote. (ISIN: SE0025011463)
What Is the Alvotech SA DRC Stock Price Today?
The Alvotech SA DRC stock price today is 36.65.
What Is the Stock Symbol for Alvotech SA DRC?
The stock symbol for Alvotech SA DRC is "ALVOsdb."
What Stock Exchange Does Alvotech SA DRC Trade On?
Alvotech SA DRC is listed and trades on the Stockholm stock exchange.
Is Alvotech SA DRC a Good Stock to Buy?
Determining whether Alvotech SA DRC, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALVOsdb quote. (ISIN: SE0025011463)
Stockholm
Currency in SEK
36.65
-0.30(-0.81%)
Closed·
Fair Value
An estimate of a Alvotech DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.75
37.00
52 wk Range
27.50
90.50
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a Alvotech DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.7537.00
52 wk Range
27.5090.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALVOsdb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Alvotech DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
60.00
Upside
+63.71%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Operates with a moderate level of debt
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 60.00
(+63.71% Upside)
Earnings
Latest Release
May 06, 2026
EPS / Forecast
-0.83 / 0.01
Revenue / Forecast
974.27M / 1.22B
Compare ALVOsdb to Peers and Sector
Metrics to compare | ALVOsdb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALVOsdbPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 13.2x | −0.4x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | 0.0x | 1.9x | 2.6x | |
Price / LTM Sales | 0.0x | 4.4x | 3.0x | |
Upside (Analyst Target) | 0.0% | 69.0% | 50.7% | |
Fair Value Upside | Unlock | 18.6% | 7.2% | Unlock |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alvotech DRC (ALVOsdb) Stock Price Today?
The Alvotech DRC stock price today is 36.65 SEK.
What Stock Exchange Does Alvotech DRC Trade On?
Alvotech DRC is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Alvotech DRC?
The stock symbol for Alvotech DRC is "ALVOsdb."
What Is the Alvotech DRC Market Cap?
As of today, Alvotech DRC market cap is 12.85B SEK.
What Is Alvotech DRC's Earnings Per Share (TTM)?
The Alvotech DRC EPS (TTM) is -0.28.
When Is the Next Alvotech DRC Earnings Date?
Alvotech DRC will release its next earnings report on Aug 19, 2026.
From a Technical Analysis Perspective, Is ALVOsdb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Alvotech DRC Stock Split?
Alvotech DRC has split 0 times.
How Many Employees Does Alvotech DRC Have?
Alvotech DRC has 1279 employees.
What is the current trading status of Alvotech DRC (ALVOsdb)?
As of Aug 07, 2026, Alvotech DRC (ALVOsdb) is trading at a price of 36.65 SEK, with a previous close of 36.95 SEK. The stock has fluctuated within a day range of 35.75 SEK to 37.00 SEK, while its 52-week range spans from 27.50 SEK to 90.50 SEK.
What Is Alvotech DRC (ALVOsdb) Price Target According to Analysts?
The average 12-month price target for Alvotech DRC is 60.00 SEK, with a high estimate of 60 SEK and a low estimate of 60 SEK. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +63.71% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.